MannKind Corporation (MNKD): Price and Financial Metrics


MannKind Corporation (MNKD): $4.44

-0.13 (-2.84%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MNKD to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MNKD POWR Grades


  • Value is the dimension where MNKD ranks best; there it ranks ahead of 50.89% of US stocks.
  • The strongest trend for MNKD is in Quality, which has been heading down over the past 179 days.
  • MNKD's current lowest rank is in the Growth metric (where it is better than 1.1% of US stocks).

MNKD Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for MNKD is -0.36 -- better than merely 4.94% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.51 for Mannkind Corp; that's greater than it is for only 4.51% of US stocks.
  • With a year-over-year growth in debt of 210.07%, Mannkind Corp's debt growth rate surpasses 94.73% of about US stocks.
  • Stocks that are quantitatively similar to MNKD, based on their financial statements, market capitalization, and price volatility, are ZKIN, CYRX, ACRX, KALA, and ATEC.
  • Visit MNKD's SEC page to see the company's official filings. To visit the company's web site, go to www.mannkindcorp.com.

MNKD Valuation Summary

  • MNKD's price/earnings ratio is -13.9; this is 138.08% lower than that of the median Healthcare stock.
  • Over the past 208 months, MNKD's price/sales ratio has gone NA NA.
  • Over the past 208 months, MNKD's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for MNKD.

Stock Date P/S P/B P/E EV/EBIT
MNKD 2021-08-31 16.1 -6.5 -13.9 -19.8
MNKD 2021-08-30 15.8 -6.4 -13.7 -19.5
MNKD 2021-08-27 16.5 -6.7 -14.2 -20.1
MNKD 2021-08-26 15.5 -6.3 -13.4 -19.2
MNKD 2021-08-25 15.4 -6.3 -13.3 -19.1
MNKD 2021-08-24 14.9 -6.0 -12.9 -18.5

MNKD Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at 80.29%.
  • The 2 year revenue growth rate now stands at 406.72%.
  • Its 4 year net cashflow from operations growth rate is now at 3.19%.
MNKD's revenue has moved up $33,600,000 over the prior 34 months.

The table below shows MNKD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 75.442 -61.709 -80.926
2021-09-30 81.37 -49.127 -79.276
2021-06-30 74.511 -47.403 -86.105
2021-03-31 66.345 -29.64 -60.834
2020-12-31 65.144 -28.128 -57.24
2020-09-30 62.694 -33.47 -45.092

MNKD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MNKD has a Quality Grade of C, ranking ahead of 42.97% of graded US stocks.
  • MNKD's asset turnover comes in at 0.384 -- ranking 124th of 680 Pharmaceutical Products stocks.
  • VERU, PLX, and LGND are the stocks whose asset turnover ratios are most correlated with MNKD.

The table below shows MNKD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.384 0.611 -0.321
2021-03-31 0.424 0.627 -0.330
2020-12-31 0.673 0.622 -0.564
2020-09-30 0.673 0.595 -0.391
2020-06-30 0.666 0.529 -0.297
2020-03-31 0.705 0.516 -0.324

MNKD Price Target

For more insight on analysts targets of MNKD, see our MNKD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.17 Average Broker Recommendation 1.33 (Strong Buy)

MNKD Stock Price Chart Interactive Chart >

Price chart for MNKD

MNKD Price/Volume Stats

Current price $4.44 52-week high $5.53
Prev. close $4.57 52-week low $2.49
Day low $4.28 Volume 9,324,600
Day high $4.66 Avg. volume 3,771,921
50-day MA $3.51 Dividend yield N/A
200-day MA $4.08 Market Cap 1.12B

MannKind Corporation (MNKD) Company Bio


MannKind Corporation focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. The company was founded in 1991 and is based in Valencia, California.


MNKD Latest News Stream


Event/Time News Detail
Loading, please wait...

MNKD Latest Social Stream


Loading social stream, please wait...

View Full MNKD Social Stream

Latest MNKD News From Around the Web

Below are the latest news stories about Mannkind Corp that investors may wish to consider to help them evaluate MNKD as an investment opportunity.

MannKind Corporation (MNKD) Q4 2021 Earnings Call Transcript

As a reminder, this call is being recorded on February 24, 2022, and will be available for playback on the MannKind Corporation's website shortly after the conclusion of this call until March 10, 2022. Joining us today for MannKind are chief executive officer, Michael Castagna; and chief financial officer, Steven Binder.

Yahoo | February 25, 2022

MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results

Conference Call to Begin Today at 5:00 p.m. (ET) 2021 Total Revenues of $75.4 million; +16% vs. 2020 4Q 2021 Afrezza Net Revenue of $11.3 million; +13% vs. 4Q 2020$260.7 million of Cash, Cash Equivalents and Investments at December 31, 2021Commenced clofazimine Phase 1 clinical trial in 1Q 2022Tyvaso DPI review deadline extended to May 2022 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the f

Yahoo | February 24, 2022

Update on Tyvaso DPI™ New Drug Application

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, was informed that the U.S. Food and Drug Administration (FDA) issued an information request to United Therapeutics Corporation earlier this month regarding the New Drug Application (NDA) for Tyvaso DPI, requesting additional information re

Yahoo | February 24, 2022

MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2021 fourth quarter and full year financial results, and its management will host a conference call to discuss the financial results and corporate updates at 5:00 p.m. (Eastern Time) on Thursday, February 24, 2022. Presenting from the Company will be its Chief Executive Officer Michael Castagna and Chief Financial Officer Steven Binder. Those interested in listening

Yahoo | February 21, 2022

MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference

DANBURY, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 pm (ET). Interested parties can access a link to the webcast fro

Yahoo | February 10, 2022

Read More 'MNKD' Stories Here

MNKD Price Returns

1-mo 37.46%
3-mo 63.24%
6-mo -4.31%
1-year 0.45%
3-year 270.00%
5-year 192.11%
YTD 1.60%
2021 39.62%
2020 142.64%
2019 21.70%
2018 -54.31%
2017 -27.50%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5884 seconds.